BCL2L1 and lung adenocarcinoma: A-1331852, an orally available, potent, and highly selective Bcl-xL inhibitor, reduces TAN survival and burden while sparing peripheral blood neutrophils in the KrasFrt-STOP-Frt-G12D/WT; p53Frt/Frt (hereafter called KP) mouse model of lung adenocarcinoma (LUAD), and its long-term use diminishes lung tumor growth.